New England Journal of Medicine · 2008 · 1.9K citations · 21 references
MedicineGeneticsOphthalmologyGene TherapyOcular DiseaseVisual DisordersOcular Gene DeliveryOcular Gene TherapyRetinal Pigment EpitheliumVisual ImpairmentGene-targeted TherapyInherited Retinal Disease Gene TherapyLeber Congenital Amaurosis TherapyOptogenetic Gene TherapyPeripheral Visual AcuityPeripheral Visual FieldVisual Acuity ImpairmentVisual Function Loss
Early‑onset, severe retinal dystrophy caused by RPE65 mutations leads to poor vision at birth and complete vision loss in early adulthood. The study delivered subretinal injections of recombinant AAV2/2 carrying RPE65 cDNA driven by a human RPE65 promoter to three young adults. The therapy was well tolerated with no serious adverse events, did not change visual acuity, peripheral fields, or ERG in all patients, but one patient showed marked improvement in microperimetry, dark‑adapted perimetry, and subjective visual mobility, supporting further trials. ClinicalTrials.gov identifier NCT00643747.
Early-onset, severe retinal dystrophy caused by mutations in the gene encoding retinal pigment epithelium-specific 65-kD protein (RPE65) is associated with poor vision at birth and complete loss of vision in early adulthood. We administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human RPE65 promoter. There were no serious adverse events. There was no clinically significant change in visual acuity or in peripheral visual fields on Goldmann perimetry in any of the three patients. We detected no change in retinal responses on electroretinography. One patient had significant improvement in visual function on microperimetry and on dark-adapted perimetry. This patient also showed improvement in a subjective test of visual mobility. These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747 [ClinicalTrials.gov]... ).
21
Gene therapy restores vision in a canine model of childhood blindness
Gregory M. Acland, Jharna Ray, Qí Zhāng et al. · Nature Genetics · 2001 · 1.2K citations
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
T. Michael Redmond, Shirley Yu, Eric Lee et al. · Nature Genetics · 1998 · 930 citations
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Sumin Gu, Debra A. Thompson, C.R. Srikumari et al. · Nature Genetics · 1997 · 666 citations